摘要
目的探讨依洛尤单抗联合阿托伐他汀治疗对极高危动脉粥样硬化性心血管疾病(ASCVD)患者的降脂效果。方法回顾性分析2020年1—10月山西医科大学第二医院62例行冠状动脉造影明确诊断为冠心病且合并冠状动脉多支病变的极高危ASCVD患者的临床资料,根据降脂方案分为联合组(依洛尤单抗+阿托伐他汀20 mg)31例和对照组(阿托伐他汀20 mg)31例。比较两组治疗前及治疗4周后总胆固醇(CHOL)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、空腹血糖(GLU)水平及血脂降幅,评价两组降脂效果。结果联合组和对照组治疗4周CHOL、LDL-C水平较治疗前降低(P<0.05);联合组dCHOL、dLDL-C降幅优于对照组(P<0.05);联合组降脂有效率为80.64%高于对照组的54.84%,差异有统计学意义(P<0.05)。结论依洛尤单抗注射液联合阿托伐他汀及单用阿托伐他汀均可降低CHOL、LDL-C水平,其中联合应用的降脂效果更优,且未出现血糖升高。
Objective To explore the effect of evolocumab combined with atorvastatin on lipid-lowering therapy in patients with very high-risk ASCVD.Methods A retrospective analysis of the clinical data of 62 patients with high-risk ASCVD risk who underwent coronary angiography in our hospital from January 2020 to October 2020 who were clearly diagnosed as coronary heart disease and complicated with multivessel coronary artery disease.According to the lipid-lowering program There were 31 cases in the combination group and 31 cases in the control group.The combination group was treated with evolocumab combined with atorvastatin,and the control group was treated with only atorvastatin.Comparison of total cholesterol(CHOL),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),fasting blood glucose(GLU)and blood lipid reduction before treatment and 4 weeks after treatment Level,evaluate the efficacy of lipid-lowering drugs in the two groups.Results After treatment,the levels of chol and LDL-C in the combined group and the control group were lower than those before treatment(P<0.05).The decrease of dchol and LDL-C in the combined group was better than that in the control group(P<0.05).The effective rate of lipid-lowering in the combined group was 80.64%,which was higher than 54.84%in the control group,and the difference was statistically significant(P<0.05).Conclusion evolocumab injection combined with atorvastatin and atorvastatin can significantly reduce the levels of CHOL and LDL-C,and the effect of combined application is better,and does not affect fasting blood glucose.
作者
杨志英
曹玲
蒙伟豪
周华
YANG Zhiying;CAO Ling;MENG Weihao;ZHOU Hua(Shanxi Medical University,Taiyuan 030000,China;Department of Cardiology,the Second Hospital of Shanxi Medical University,Taiyuan 030000,China)
出处
《中国全科医学》
CAS
北大核心
2021年第S01期26-29,共4页
Chinese General Practice
